PROK - NASDAQ

ProKidney Corp.

ProKidney Corp.

PROK·NASDAQ

$1.73

-8.9%
HealthcareBiotechnology

ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$581.72M
EPS-0.5200
P/E Ratio-3.33
Earnings Date08/06/2026

prok

Research Development Expenses

Last Annual Value

114.12M

3-Year CAGR

12%

5-Year CAGR

40%

10-Year CAGR

4%

ProKidney Corp.

ProKidney Corp. Competitors Analysis of research-development-expenses

PROK · NASDAQ
Companyresearch-development-expenses
CAGR 3Y
CAGR 5Y
CAGR 10Y
PROK logo
ProKidney Corp.
NASDAQ:PROK
114.12M
2.3%19.8%N/A 
SEPN logo
Septerna, Inc.
NASDAQ:SEPN
97.58M
39.5%N/AN/A
KURA logo
Kura Oncology, Inc.
NASDAQ:KURA
251.07M
29.6%24.3%28.5%
PRME logo
Prime Medicine, Inc.
NASDAQ:PRME
160.64M
2.8%17.9%N/A
SVRA logo
Savara Inc.
NASDAQ:SVRA
81.40M
22.5%22.9%25.8%
BCAX logo
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
125.10M
59.9%N/AN/A
ANAB logo
AnaptysBio, Inc.
NASDAQ:ANAB
135.97M
-0.9%6.7%19.6%
MRVI logo
Maravai LifeSciences Holdings, Inc.
NASDAQ:MRVI
23.33M
10.5%8.9%N/A
PGEN logo
Precigen, Inc.
NASDAQ:PGEN
41.33M
-5.3%-2.9%-9.5%
PHAT logo
Phathom Pharmaceuticals, Inc.
NASDAQ:PHAT
32.78M
-13.1%-14.6%N/A
XNCR logo
Xencor, Inc.
NASDAQ:XNCR
239.43M
-1.9%4.5%16.5%
ProKidney Corp.

ProKidney Corp. Fair Value Envelope

PROK · NASDAQ

Our analysis suggests that PROK has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.73, this represents a potential HIDDEN relative to our calculated worth for ProKidney Corp..

HIDDEN
Intrinsic Value
Current Price: $1.73

Related Guides

Blog Categories

Continue your PROK research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.